{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.526.3.1287","meta":{"versionId":"19","lastUpdated":"2022-03-02T18:02:48.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"PCPI Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2022-03-02"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1287","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.526.3.1287"}],"version":"20170926","name":"IntoleranceToAntineoplasticTherapy","title":"Intolerance to Antineoplastic Therapy","status":"active","experimental":false,"date":"2022-03-03T18:46:01-05:00","publisher":"PCPI Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Under Development),(Data Element Scope: Under Development),(Inclusion Criteria: Under Development),(Exclusion Criteria: Under Development)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1382"]}]},"expansion":{"identifier":"urn:uuid:88f3b93d-b218-4efc-b8d0-9c715fc800ca","timestamp":"2023-12-11T02:54:41-05:00","total":2,"contains":[{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"292196008","display":"Antineoplastic adverse reaction (disorder)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20230901","code":"292234002","display":"Fluorouracil adverse reaction (disorder)"}]}}